Soligenix, Inc. (SNGX:NASDAQ) closed at $0.365 on October 23, 2026, up 0.14% on the day. The stock trades 78.5% below its 52-week high of $1.70 and 30.4% above its 52-week low of $0.280. Over the past year, it lost 77.2%. Soligenix, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 22, 2025, SNGX closed higher on 92 days (37%). Its best day was May 27, 2026 (+70.59%) and its worst was April 28, 2026 (-70.42%). The stock moved 10% or more in a single session 16 times. It opened at least 5% above the previous day's high 1 time.
Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases primarily in the United States. It operates through two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis. This segment also offers SGX942, a novel innate defense regulator technology that is in Phase II clinical trial to treat oral mucositis in head and neck cancer. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has been completed Phase IB clinical trial for the treatment of vaccine against ricin toxin poisoning; VeloThrax, an anthrax vaccine candidate; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioid...
Find more stocks like SNGX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.